<DOC>
	<DOCNO>NCT00263965</DOCNO>
	<brief_summary>This 16-week randomized , double-blind , parallel-group , multi-center , placebo- active- ( metformin 1.5 g ) control study tesaglitazar ( 1 mg ) patient type 2 diabetes . After 1-week enrollment period , 3 week placebo single blind run period 1-week placebo single-blind baseline measurement period , patient give investigational product 16 week double blind fashion . Metformin titrate first 3 week double-blind period . The total study duration , include enrollment , run-in , randomize treatment follow-up , 29 week .</brief_summary>
	<brief_title>ARAMIS : Actions tesaglitazaR fAt Metabolism Insulin Sensitivity</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Provision write informed consent Men woman 3070 year age Female patient : postmenopausal , hysterectomized Diagnosed type 2 diabetes Treated diet alone treatment single oral antidiabetic agent low dos two oral antidiabetic agent Type 1 diabetes New York Heart Association heart failure Class III IV Treatment chronic insulin History hypersensitivity intolerance peroxisome proliferatoractivated receptor agonist ( like Actos Avandia ) , fenofibrate , metformin 3hydroxy3methylglutaryl coenzyme A reductase inhibitor ( statin ) History druginduced myopathy druginduced creatine kinase elevation , liver enzyme elevation , neutropenia ( low white blood cell ) Creatinine level twice normal range Creatine kinase 3 time upper limit normal Received investigational product clinical study within 12 week Any clinically significant abnormality identify physical examination , laboratory test electrocardiogram , judgment investigator would compromise patient 's safety successful participation clinical study</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>